KRAS-IN-49
KRAS-IN-49 (compound 7b) is a selective and covalent KRAS G13C inhibitor. KRAS-IN-49 covalently binds to Cys13 of KRAS G13C. KRAS-IN-49 can be used for non-small cell lung cancer (NSCLC) research[1].
Product Specifications
UNSPSC
12352005
Target
Ras
Related Pathways
GPCR/G Protein; MAPK/ERK Pathway
Field of Research
Cancer
Smiles
O=C1C(N=CN2[C@@H]3O[C@H](COP(OP(O)(O)=O)(O)=O)[C@@H](OC(N4CCC[C@@H](NC(C=C)=O)C4)=O)[C@H]3OC(N5C[C@@H](CCC5)NC(C=C)=O)=O)=C2N=C(N)N1
Molecular Formula
C28H39N9O15P2
Molecular Weight
803.61
References & Citations
[1]Kirschner T, et al. Targeting KRASG13C with cyclic linker based inhibitors to explore warhead orientation. Sci Rep. 2025 Oct 31;15 (1) :38213.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS2160253-01 96 Tests
Tumor Necrosis Factor Alpha Induced Protein 2 (TNFaIP2) Magnetic Fluorescence Assay Kit
Ask
View Details MBS2160253-02 5x 96 Tests
Tumor Necrosis Factor Alpha Induced Protein 2 (TNFaIP2) Magnetic Fluorescence Assay Kit
Ask
View Details MBS2160253-03 10x 96 Tests
Tumor Necrosis Factor Alpha Induced Protein 2 (TNFaIP2) Magnetic Fluorescence Assay Kit
Ask
View Details GTR15101665 1 Vial
Lentiviral human WBP2NL shRNA (UAS) - Lentiviral human WBP2NL shRNA (UAS, RFP) plasmid
Ask
View Details